1、SustainabilityReport2022AssuranceBureau Veritas has provided limited assurance for sustainability activities reported in the Sustainability Data Summary 2022 and in the Annual Report 2022.Details are described in the Letters of Assurance,which are publicly available.Assurance is in accordance with t

2、he International Standard on Assurance Engagements(ISAE)3000(Revised),Assurance Engagements Other than Audits or Reviews of Historical Financial Information,and with International Standard on Assurance Engagements 3410 Assurance Engagements on Greenhouse Gas Statements(ISAE 3410),issued by the Inter

3、national Auditing and Assurance Standards Board.AstraZeneca has reported the information cited in this GRI content index for the period from 1 January 2022 to 31 December 2022,with reference to the GRI Standards.Next generation therapeutics Advancements in biotechnology have expanded our toolkit of

4、drug modalities.This provides an opportunity to design therapeutics for disease mechanisms previously considered difficult,if not impossible,to target and enables our scientists to pioneer new approaches to drug discovery.ContentsFootnotes 35This is our eighth annual sustainability report and it des

5、cribes our approach and progress from 1 January 2022 to 31 December 2022,unless otherwise stated.The content is based on those sustainability focus areas deemed material through comprehensive stakeholder engagement and analysis.Allour business operations worldwide are in scope regardless of their fu

6、nction,unlessotherwise stated.Online resources:AstraZeneca Sustainability Data Summary:provides performance measures and targets with at least three years of data,where available,and a United Nations Sustainable Development Goals index.AstraZeneca Sustainability webpages:cover additional topics of i